Turning Point Therapeutics, Inc. TPTX
We take great care to ensure that the data presented and summarized in this overview for Turning Point Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in TPTX
Top Purchases
Top Sells
About TPTX
Insider Transactions at TPTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 17
2022
|
Paolo Tombesi EVP & Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
29,778
-100.0%
|
$2,263,128
$76.0 P/Share
|
|
Aug 17
2022
|
Brian Sun SVP & General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
45,000
-100.0%
|
$3,420,000
$76.0 P/Share
|
|
Aug 17
2022
|
Steve M Sabus SVP & Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
36,667
-100.0%
|
$2,786,692
$76.0 P/Share
|
|
Aug 17
2022
|
Mohammad Hirmand EVP and Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
41,284
-100.0%
|
$3,137,584
$76.0 P/Share
|
|
Aug 17
2022
|
Simeon George Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
2,253,660
-100.0%
|
$171,278,160
$76.0 P/Share
|
|
Aug 17
2022
|
Athena Countouriotis President & CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
110,959
-100.0%
|
$8,432,884
$76.0 P/Share
|
|
Aug 17
2022
|
Mark J Alles Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,000
-100.0%
|
$152,000
$76.0 P/Share
|
|
Jul 27
2022
|
Paolo Tombesi EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,183
-3.96%
|
$87,542
$74.94 P/Share
|
|
May 31
2022
|
Steve M Sabus SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,667
+50.0%
|
-
|
|
Apr 11
2022
|
Brian Sun SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+50.0%
|
-
|
|
Feb 09
2022
|
Athena Countouriotis President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
62,400
+36.13%
|
-
|
|
Feb 09
2022
|
Athena Countouriotis President & CEO |
SELL
Open market or private sale
|
Direct |
2,971
-5.84%
|
$106,956
$36.3 P/Share
|
|
Feb 09
2022
|
Mohammad Hirmand EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,983
+34.62%
|
-
|
|
Feb 09
2022
|
Mohammad Hirmand EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
669
-8.91%
|
$24,084
$36.3 P/Share
|
|
Feb 09
2022
|
Annette North EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
16,283
+36.79%
|
-
|
|
Feb 09
2022
|
Annette North EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
669
-5.41%
|
$24,084
$36.3 P/Share
|
|
Feb 09
2022
|
Andrew John Partridge EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,283
+29.8%
|
-
|
|
Feb 09
2022
|
Andrew John Partridge EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
221
-0.99%
|
$7,956
$36.3 P/Share
|
|
Feb 09
2022
|
Siegfried Reich EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,567
+44.36%
|
-
|
|
Feb 09
2022
|
Siegfried Reich EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
397
-10.33%
|
$14,292
$36.3 P/Share
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders